NEW YORK (GenomeWeb News) — Invitrogen has started a new program to screen technologies from third party companies against its own cell-culture products, the company said today.
 
Invitrogen also clarified the terms of its recent collaboration with Viropro, which falls under this screening program, saying it would not pay royalties or take commercial interest in any licensing of the technologies.
  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.